title: Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN 46285, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Cassidy
authors.forename: P
authors.initials: P
authors.lastname: Peterson
authors.forename: L
authors.initials: L
authors.lastname: Cirera
authors.forename: D F
authors.initials: DF
authors.lastname: Roychowdhury
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015897:Comorbidity; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D015994:Incidence; D017713:Platelet Transfusion; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine